Foghorn Therapeutics (Nasdaq: FHTX) Cuts 40% of Staff as Eli Lilly (NYSE: LLY) Partnership Ends
Disappointing early clinical activity forces a return to a smaller, preclinical pipeline.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
Foghorn Therapeutics is reducing its workforce by 40% after it and Lilly decided to end their collaboration. The decision follows a review of Phase I dose-escalation data for FHD-909, also known as LY4050784, which did not support further development.
The investigational cancer medicine targeted SMARCA2. According to Foghorn, the compound reached exposures above its preclinical targets with a favourable safety profile, but the underlying biological hypothesis did not translate into sufficient efficacy. The partnership's other programmes are also being discontinued.
Foghorn expects the restructuring to leave approximately 65 full-time employees and fund its priority programmes into the second half of 2029. Attention shifts to earlier assets, including its EP300 degrader programme.
The distinction between hitting a molecular target and treating a disease is central here. Pharmacological activity can validate drug design without validating the investment case. A longer cash runway gives Foghorn time to pursue other approaches, but the remaining portfolio will need to rebuild clinical evidence from an earlier starting point.